Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S2005 Raltegravir (MK-0518) <1 mg/mL 88 mg/mL <1 mg/mL
S2001 Elvitegravir (GS-9137, JTK-303) <1 mg/mL 89 mg/mL 35 mg/mL
S2667 Dolutegravir (GSK1349572) <1 mg/mL 83 mg/mL <1 mg/mL
S1366 BMS-707035 <1 mg/mL 38 mg/mL <1 mg/mL
S2765 MK-2048 <1 mg/mL 9 mg/mL <1 mg/mL
S5911 Bictegravir <1 mg/mL 90 mg/mL <1 mg/mL
S5245 Raltegravir potassium <1 mg/mL 96 mg/mL 10 mg/mL
S7766 Cabotegravir (GSK744, GSK1265744) <1 mg/mL 38 mg/mL <1 mg/mL
S4642 Dolutegravir Sodium <1 mg/mL 0.2 mg/mL <1 mg/mL
S4187 Salicylanilide <1 mg/mL 43 mg/mL 18 mg/mL
Catalog No. Information Product Use Citations Product Validations

Raltegravir (MK-0518)

Raltegravir (MK-0518) is a potent integrase (IN) inhibitor for WT and S217Q PFV IN with IC50 of 90 nM and 40 nM in cell-free assays, respectively. It shows greater than 1000-fold selectivity for HIV-1 IN over several related Mg2+-dependent enzyme such as HCV polymerase, HIV reverse transcriptase, HIV RNaseH and human α-, β-, γ-polymerases.


Elvitegravir (GS-9137, JTK-303)

Elvitegravir (GS-9137, JTK-303) is an HIV integrase inhibitor for HIV-1 IIIB, HIV-2 EHO and HIV-2 ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM in cell-free assays, respectively.


Dolutegravir (GSK1349572)

Dolutegravir (GSK1349572) is a two-metal-binding HIV integrase inhibitor with IC50 of 2.7 nM in a cell-free assay, modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.



BMS-707035 is a specific HIV-I integrase (IN) inhibitor with IC50 of 15 nM. Phase 2.



MK-2048 is a potent inhibitor of integrase (IN) and INR263K with IC50 of 2.6 nM and 1.5 nM, respectively.



Bictegravir is a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase.


Raltegravir potassium

Raltegravir Potassium is the orally bioavailable potassium salt of raltegravir, the first approved human immunodeficiency virus type 1 (HIV-1) integrase inhibitor.


Cabotegravir (GSK744, GSK1265744)

Cabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor against a broad range of HIV subtypes, and inhibits the HIV-1 integrase catalyzed strand transfer reaction with IC50 of 3.0 nM. Phase 2.


Dolutegravir Sodium

Dolutegravir sodium is a HIV integrase inhibitor with IC50 of 2.7 nM.



Salicylanilides are a group of compounds with a wide range of biological activities including antiviral potency, antibacterial (including antimycobacterial) and antifungal activities.

Tags: Integrase activity | Integrase inhibitors mechanism | HIV Integrase inhibitor mechanism | Integrase assay | HIV Integrase assay | Integrase inhibitor drugs | HIV Integrase inhibitor drugs | Integrase inhibitor resistance testing | Integrase inhibitor review